By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Visterra, Inc. 

One Kendall Square
Suite B3301
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-498-1070 Fax: 617-498-1073


SEARCH JOBS


Industry
Biotechnology






Company News
Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference 8/25/2016 11:21:51 AM
Visterra, Inc. To Present New Clinical Results Of VIS410 At The Options IX For The Control Of Influenza Conference 8/24/2016 11:26:36 AM
Visterra, Inc. Appoints Two Industry Leaders To Its Board Of Directors 4/21/2016 11:03:44 AM
Visterra, Inc. Announces Publication Of Clinical Data On VIS410 In The Journal EBioMedicine 2/26/2016 8:22:36 AM
Visterra, Inc.’s Monoclonal Antibody In Development For The Treatment Of Influenza A, VIS410, Demonstrated Significant Antiviral Activity And Reduced Duration Of Respiratory Symptoms In Phase IIa Challenge Study 10/5/2015 10:31:10 AM
Visterra, Inc. Awarded Contract Valued at Up to $204.5 Million 10/5/2015 8:24:44 AM
Visterra, Inc. And Serum Institute of India, Ltd. Announce Collaboration To Advance VIS513, A Monoclonal Antibody In Development For The Treatment Of Dengue, In The Indian Subcontinent 9/9/2015 11:18:31 AM
Visterra, Inc. Announces Appointment Of John Weidenbruch As General Counsel 9/2/2015 10:51:08 AM
Visterra, Inc. Announces Publication Of Data Demonstrating The Effectiveness Of VIS410 Against Seasonal And Potential Pandemic Influenza Strains 8/18/2015 8:34:08 AM
Visterra, Inc. Announces Publication In The Journal Cell, Demonstrating That Novel Antibody, VIS513, Broadly Neutralizes All Four Serotypes Of Dengue Virus In Preclinical Studies 7/17/2015 9:11:24 AM
123
//-->